Goldman Sachs Group Inc Sage Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

  • $613 Billion
  • Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 542,247 shares of SAGE stock, worth $4.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
542,247
Previous 770,321 29.61%
Holding current value
$4.01 Million
Previous $5.55 Million 46.99%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
SELL
$4.78 - $8.57 $1.09 Million - $1.95 Million
-228,074 Reduced 29.61%
542,247 $2.94 Million
Q3 2024

Nov 14, 2024
BUY
$7.02 - $13.08 $131,667 - $245,328
18,756 Added 2.5%
770,321 $5.55 Million
Q2 2024

Aug 13, 2024
BUY
$10.58 - $17.9 $2.42 Million - $4.09 Million
228,311 Added 43.63%
751,565 $8.16 Million
Q1 2024

May 15, 2024
BUY
$18.62 - $26.95 $870,447 - $1.26 Million
46,748 Added 9.81%
523,254 $9.81 Million
Q4 2023

Feb 13, 2024
BUY
$17.1 - $22.26 $2.79 Million - $3.64 Million
163,400 Added 52.19%
476,506 $10.3 Million
Q3 2023

May 14, 2024
SELL
$16.75 - $48.98 $2.74 Million - $8 Million
-163,400 Reduced 34.29%
313,106 $6.44 Million
Q3 2023

Nov 14, 2023
SELL
$16.75 - $48.98 $3.33 Million - $9.74 Million
-198,859 Reduced 38.84%
313,106 $6.44 Million
Q2 2023

May 14, 2024
SELL
$40.65 - $59.54 $17.6 Million - $25.9 Million
-434,173 Reduced 45.89%
511,965 $24.1 Million
Q2 2023

Aug 14, 2023
SELL
$40.65 - $59.54 $17.6 Million - $25.9 Million
-434,173 Reduced 45.89%
511,965 $24.1 Million
Q1 2023

May 14, 2024
BUY
$37.27 - $46.57 $819 - $1,024
22 Added 0.0%
946,138 $39.7 Million
Q1 2023

May 11, 2023
BUY
$37.27 - $46.57 $819 - $1,024
22 Added 0.0%
946,138 $39.7 Million
Q4 2022

May 14, 2024
SELL
$32.2 - $43.61 $5.33 Million - $7.21 Million
-165,406 Reduced 14.88%
946,116 $36.1 Million
Q4 2022

Feb 13, 2023
SELL
$32.2 - $43.61 $5.33 Million - $7.21 Million
-165,406 Reduced 14.88%
946,116 $36.1 Million
Q3 2022

May 14, 2024
BUY
$32.28 - $43.27 $169,340 - $226,994
5,246 Added 0.47%
1,111,522 $43.5 Million
Q3 2022

Nov 10, 2022
BUY
$32.28 - $43.27 $169,340 - $226,994
5,246 Added 0.47%
1,111,522 $43.5 Million
Q2 2022

May 14, 2024
BUY
$27.52 - $37.99 $17.3 Million - $23.9 Million
629,770 Added 132.16%
1,106,276 $35.7 Million
Q2 2022

Aug 15, 2022
BUY
$27.52 - $37.99 $21.8 Million - $30.1 Million
792,819 Added 252.93%
1,106,276 $35.7 Million
Q1 2022

May 16, 2022
SELL
$30.71 - $45.71 $4.04 Million - $6.01 Million
-131,502 Reduced 29.55%
313,457 $10.4 Million
Q4 2021

Feb 14, 2022
SELL
$37.06 - $47.11 $1.02 Million - $1.3 Million
-27,535 Reduced 5.83%
444,959 $18.9 Million
Q3 2021

Nov 10, 2021
BUY
$40.26 - $57.37 $19 Million - $27.1 Million
472,494 New
472,494 $20.9 Million

Others Institutions Holding SAGE

# of Institutions
194
Shares Held
45M
Call Options Held
304K
Put Options Held
117K
View Full List

About Sage Therapeutics, Inc.

SAGE Quotes by TradingView
  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $440M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email